The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA

Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA

June 1, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—A number of recent studies support last year’s update of 2010 treat-to-target recommendations for rheumatoid arthritis (RA), according to the international task force that revised them.

You Might Also Like
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • SLE Remission: The Treat-to-Target Approach
  • 2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA

Dr. Josef S. Smolen from Medical University of Vienna, Austria, and colleagues updated their 2010 advice based on systematic literature reviews and expert opinion.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

They left the overarching principles largely unchanged, and the final set of 10 recommendations continue to emphasize clinical remission—defined as the absence of signs and symptoms of significant inflammatory disease activity—as the primary treatment target.

“The new recommendations of the task force seem similar to the 2010 recommendations, but they are supported with much more scientific evidence,” rheumatologist Dr. Antonio Naranjo Hernandez from Hospital Universitario de Gran Canaria Doctor Negrin in Las Palmas de Gran Canaria, Spain, told Reuters Health by email. He was not involved in the task force.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Slight changes include changing the monitoring for disease activity in patients with low disease activity or remission from “such as every 3-6 months” to “such as every six months” and the re-emphasis in the final recommendation that “the rheumatologist should involve the patient in setting the treatment target and the strategy to reach this target.”

Originally only two recommendations had the highest levels of supportive evidence (1 or 2), while seven do so now, according to the report, online May 12 in the Annals of the Rheumatic Diseases.

And four recommendations in 2010 had levels of agreement below 9 (out of 10), whereas all recommendations in 2014 carry levels of agreement of 9 or higher.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“While recommendations like the ones presented here may be able to summarise the current state of evidence and provide the respective target audience with some guidance, their implementation is difficult to follow,” the task force writes. “Evaluating the implementation of the treat-to-target (T2T) strategy is clearly an additional important research aspect of the future.”

“In summary,” the report concludes, “the updated version of the treat-to-target recommendations have brought this guidance document to a new level regarding evidence and agreement and will hopefully be adopted by the community of rheumatologists, patients and the other stakeholders.”

“Regular assessment of disease activity and shared decision making with the patients” are the recommendations that deserve the greatest emphasis, Dr. Naranjo said.

He said the best way to achieve these goals is to have a dedicated RA clinic with specialized nurses assigned to patients. “The role of imaging in tight control is now being investigated to show us, for example, if a treat-to-target based on ultrasonography would be superior to the clinical indices,” he added.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: recommendation, Remission, Rheumatiod arthritis

You Might Also Like:
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • SLE Remission: The Treat-to-Target Approach
  • 2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA
  • Treat Rheumatoid Arthritis to Target

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.